US Patent Issued to AC IMMUNE on May 12 for "Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway" (Swiss, French Inventors)

ALEXANDRIA, Va., May 12 -- United States Patent no. 12,624,010, issued on May 12, was assigned to AC IMMUNE SA (Lausanne, Switzerland).

"Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway" was invented by Emanuele Gabellieri (Le mont sur Lausanne, Switzerland), Jerome Molette (Prevessin-Moens, France) and Veronique Dehlinger (Morges, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to novel compounds for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a component of the NLRP3 inflammasome pathway. In particular, the compo...